Microplastics and Misinformation: What Science Really Says
November 12, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
SandoptalÂ
Synonyms :
Allylbarbital, Allylbarbitone, Allylbarbituric acid, Butalbarbital, butalbital, Butalbitalum, iso-butylallylbarbituric acid, Itobarbital, Tetrallobarbital
Class :
Neuropsychiatric agent, Narcotrics and psychotropicsBarbiturate sedative-hypnotics
Brand Name :
SandoptalÂ
Synonyms :
Allylbarbital, Allylbarbitone, Allylbarbituric acid, Butalbarbital, butalbital, Butalbitalum, iso-butylallylbarbituric acid, Itobarbital, Tetrallobarbital
Class :
Neuropsychiatric agent, Narcotrics and psychotropicsBarbiturate sedative-hypnotics
Dosage Forms & StrengthsÂ
Tablet (available in combination) (Schedule III)Â
50 mgÂ
Muscle Contraction Tension HeadacheÂ
This compound, in multiple combinations with other drugs, is authorized
Among them is fiorinal with codeine, a combination of butalbital, aspirin, and caffeine, which is used to treat headaches associated with stress or spasms in the muscles
Combination with other drugs:
Fiorinal with codeine, this drug combination with caffeine and aspirin, is available in the strength of 50 mg/40 mg/ 325 mg with the daily recommended dosage of 1 or 2 tablets via oral with a time-interval of 4 hours
The maximum permissible limit per day is six tablets
Dose Adjustments
Limited data is available
Dosage Forms & StrengthsÂ
Tablet (available in combination) (Schedule III)Â
50 mgÂ
Muscle Contraction Tension HeadacheÂ
This compound, in multiple combinations with other drugs, is authorized
Safety and efficacy are not seen in pediatrics below 16
Among them is fiorinal with codeine, a combination of butalbital, aspirin, and caffeine, which is used to treat headaches associated with stress or spasms in the muscles
Combination with other drugs:-
For pediatrics above 16:
Fiorinal with codeine, this drug combination with caffeine and aspirin, is available in the strength of 50 mg/40 mg/ 325 mg with the daily recommended dosage of 1 or 2 tablets via oral with a time-interval of 4 hours
Refer to the adult dosingÂ
may increase the metabolism of vitamin K antagonists
may increase the metabolism of vitamin K antagonists
may increase the metabolism of vitamin K antagonists
may increase the metabolism of vitamin K antagonists
may increase the metabolism of vitamin K antagonists
It may diminish the effect when combined with lonafarnib by affecting CYP3A4 metabolism
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the metabolism when combined with tricyclic antidepressants
may increase the action of CNS depressants inducing CNS depression
bunazosin (Not available in the United States)
may increase the action of CNS depressants inducing CNS depression
may increase the action of CNS depressants inducing CNS depression
may increase the action of CNS depressants inducing CNS depression
may increase the action of CNS depressants inducing CNS depression
may increase the metabolism of tricyclic antidepressants
may increase the metabolism of tricyclic antidepressants
may increase the metabolism of tricyclic antidepressants
may increase the metabolism of tricyclic antidepressants
may increase the metabolism of tricyclic antidepressants
may increase the metabolism of tricyclic antidepressants
bupivacaine: it may increase the risk of methemoglobinemia agents
benzyl alcohol: it may increase the risk of methemoglobinemia agents
capecitabine: it may increase the risk of methemoglobinemia agents
capsaicin: it may increase the risk of methemoglobinemia agents
diphenhydramine: it may increase the risk of methemoglobinemia agents
dyclonine: it may increase the risk of methemoglobinemia agents
estetrol: it may increase the risk of methemoglobinemia agents
furosemide: it may increase the risk of methemoglobinemia agents
levobupivacaine: it may increase the risk of methemoglobinemia agents
lidocaine: it may increase the risk of methemoglobinemia agents
mepivacaine: it may increase the risk of methemoglobinemia agents
nedaplatin: it may increase the risk of methemoglobinemia agents
acemetacin: it may increase the risk of methemoglobinemia agents
acetazolamide: it may increase the risk of methemoglobinemia agents
acetylsalicyclic acid: it may increase the risk of methemoglobinemia agents
amiloride: it may increase the risk of methemoglobinemia agents
amitriptyline: it may increase the risk of methemoglobinemia agents
ammonium chloride: it may increase the risk of methemoglobinemia agents
benorilate: it may increase the risk of methemoglobinemia agents
benserazide: it may increase the risk of methemoglobinemia agents
benzatropine: it may increase the risk of methemoglobinemia agents
bepotastine: it may increase the risk of methemoglobinemia agents
bismuth subgallate: it may increase the risk of methemoglobinemia agents
bisoxatin: it may increase the risk of methemoglobinemia agents
pheneticillin: it may increase the risk of methemoglobinemia associated agents
cinchocaine: it may increase the risk of methemoglobinemia associated agents
doxycycline: it may increase the risk of methemoglobinemia associated agents
enoxacin: it may increase the risk of methemoglobinemia associated agents
eravacycline: it may increase the risk of methemoglobinemia associated agents
moricizine: it may increase the risk of methemoglobinemia associated agents
oxybuprocaine: it may increase the risk of methemoglobinemia associated agents
piperazine: it may increase the risk of methemoglobinemia associated agents
promazine: it may increase the risk of methemoglobinemia associated agents
spirapril: it may increase the risk of methemoglobinemia associated agents
carvedilol: it may increase the risk of methemoglobinemia associated agents
ambroxol: it may increase the risk of methemoglobinemia agents
amikacin: it may increase the risk of methemoglobinemia agents
aminophenazone: it may increase the risk of methemoglobinemia agents
alteplase: it may increase the risk of methemoglobinemia agents
ceforanide: it may increase the risk of methemoglobinemia agents
bicisate: it may increase the risk of methemoglobinemia agents
bleomycin: it may increase the risk of methemoglobinemia agents
bivalirudin: it may increase the risk of methemoglobinemia agents
It may diminish the effect when combined with pemigatinib by affecting CYP3A4 metabolism
butalbital can diminish the level or impact of intranasal dihydroergotamine by influencing the metabolism of the hepatic/intestinal enzyme CYP3A4
may increase the harmful effects of CNS depressants
may increase the harmful effects of CNS depressants
may increase the harmful effects of CNS depressants
may increase the harmful effects of CNS depressants
may increase the harmful effects of CNS depressants
when both drugs are combined, there may be an increased metabolism of alpelisib   
butalbital decreases the effect of fedratinib by altering the intestinal/hepatic CYP3A4 enzyme metabolism
may increase the metabolism of each other
it decreases by affecting the hepatic enzyme CYP3A4 metabolism
may reduce the therapeutic effect of hemin
methyldopa/hydrochlorothiazideÂ
may increase the hypotensive effect of blood pressure-lowering agents
alogliptin: it may increase the risk of methemoglobinemia agents
alvimopan: it may increase the risk of methemoglobinemia agents
balsalazide: it may increase the risk of methemoglobinemia agents
methemoglobinemia associated agents may enhance the adverse/toxic effect of local anesthetics
methemoglobinemia associated agents may enhance the adverse/toxic effect of local anesthetics
methemoglobinemia associated agents may enhance the adverse/toxic effect of local anesthetics
methemoglobinemia associated agents may enhance the adverse/toxic effect of local anesthetics
methemoglobinemia associated agents may enhance the adverse/toxic effect of local anesthetics
Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents
Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents
Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents
Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents
Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents
may increase the metabolism of Vitamin K Antagonists
may increase the metabolism of Vitamin K Antagonists
may increase the metabolism of Vitamin K Antagonists
may increase the metabolism of Vitamin K Antagonists
may increase the metabolism of Vitamin K Antagonists
may increase the hypotensive effect
may increase the hypotensive effect
may increase the hypotensive effect
may increase the hypotensive effect
may increase the hypotensive effect
barbiturates may increase the metabolism of tricyclic antidepressants
barbiturates may increase the metabolism of tricyclic antidepressants
barbiturates may increase the metabolism of tricyclic antidepressants
barbiturates may increase the metabolism of tricyclic antidepressants
barbiturates may increase the metabolism of tricyclic antidepressants
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increasingly adverse effect when combined with local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
It may enhance sedation when combined with perphenazine
It may enhance sedation when combined with a shepherd's purse
It may enhance the effect when combined with cannabidiol by affecting CYP3A4 metabolism
It may diminish the effect when combined with lumateperone by affecting CYP3A4 metabolism
may have an increased hypotensive effect when combined with antihypertensive agents
barbiturates: they may increase the hypotensive effect when combined with blood viscoosity-reducing agents
barbiturates: they may increase the hypotensive effect when combined with blood viscoosity-reducing agents
methemoglobinemia associated agents: they may increase the toxic effect when combined with local anesthetics
they increase the effect of hypotension of BP-lowering agents
they increase the effect of hypotension of BP-lowering agents
they increase the effect of hypotension of BP-lowering agents
they increase the effect of hypotension of BP-lowering agents
they increase the effect of hypotension of BP-lowering agents
When butalbital is used together with bromisoval, the risk or seriousness of CNS depression is enhanced
When captodiame is used together with butalbital, there is a risk or seriousness of CNS depression is enhanced
When butalbital is used together with medazepam, the risk or seriousness of CNS depression is enhanced
When butalbital is used together with niaprazine, the risk or seriousness of CNS depression is enhanced
When butalbital is used together with levosulpiride, the risk or seriousness of CNS depression is enhanced
It may enhance the risk of adverse effects when combined with protein kinase inhibitors
It may enhance the risk of adverse effects when combined with protein kinase inhibitors
It may enhance the risk of adverse effects when combined with protein kinase inhibitors
It may enhance the risk of adverse effects when combined with protein kinase inhibitors
It may enhance the risk of adverse effects when combined with protein kinase inhibitors
When chlordiazepoxide is used together with butalbital, this leads to enhanced risk or seriousness of CNS depression
When butalbital is used together with norelgestromin, this leads to a rise in norelgestromin’s metabolism
barbiturates: they may decrease the therapeutic effect of antipsychotics
barbiturates: they may decrease the therapeutic effect of antipsychotics
barbiturates: they may decrease the therapeutic effect of antipsychotics
barbiturates: they may decrease the therapeutic effect of antipsychotics
barbiturates: they may decrease the therapeutic effect of antipsychotics
When emylcamate is used together with butalbital, this leads to enhanced risk or seriousness of CNS depression
When butalbital is used together with etizolam, this leads to enhanced risk or seriousness of CNS depression
When acepromazine is used together with butalbital, this leads to enhanced risk or seriousness of CNS depression
when butalbital is combined with aclidinium, the risk or extent of adverse effects linked to aclidinium may be heightened
the combination of butalbital and agomelatine may raise the risk or extent of CNS depression
when butalbital is combined with yohimbine, the risk or extent of CNS depression associated with yohimbine may be increased
when combined with butalbital, the risk or extent of adverse effects associated with zimelidine may be increased
Decreased therapeutic efficacy of butalbital.
when both drugs are combined, there may be an increased metabolism of paclitaxel  
when both drugs are combined, there may be a decreased level of serum concentration of erlotinib  
may enhance the hypotensive effect of blood Pressure Lowering Agents
may enhance the hypotensive effect of blood Pressure Lowering Agents
may enhance the hypotensive effect of blood Pressure Lowering Agents
may enhance the hypotensive effect of blood Pressure Lowering Agents
may enhance the hypotensive effect of blood Pressure Lowering Agents
valproate increases the concentration of serum barbiturates in the serum
may decrease the levels of each other by increasing the metabolism
may decrease the level by affecting hepatic enzyme CYP3A4 metabolism
glycopyrrolate inhaled and formoterolÂ
may decrease the toxic effects of each other by sedation
relugolix/​estradiol/​norethindroneÂ
it decreases by affecting the hepatic enzyme CYP3A4 metabolism
may increase the hypotensive effect of antihypertensives
pramoxine /hydrocortisone topicalÂ
may increase the adverse effect
may increase the hypotensive effect
may increase the toxic effect
may increase the toxic effects of local anaesthetics
may increase the hypotensive effect of anti-hypertensives
may increase the toxic effect of local anesthetics
may increase the hypotensive effect of blood pressure-lowering agents
hydrochlorothiazide/aliskirenÂ
may increase the hypotensive effect of blood pressure-lowering agents
may increase the hypotensive effect of blood pressure-lowering agents
lisinopril/hydrochlorothiazideÂ
may increase the hypotensive effect of blood pressure-lowering agents
eprosartan/hydrochlorothiazideÂ
may increase the hypotensive effect of blood pressure-lowering agents
valsartan/hydrochlorothiazideÂ
may increase the hypotensive effect of blood pressure-lowering agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increasingly adverse effect when combined with local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
may increase the hypotensive effect of blood pressure-lowering agents
may increases the adverse effect of Local Anesthetics
may increase the adverse effect of Local Anesthetics
may have an increasingly adverse effect when combined with methemoglobinemia agents
may have an increasingly adverse effect when combined with methemoglobinemia agents
may have an increasingly adverse effect when combined with prilocaine
may increase the hypotensive effect of Blood Pressure Lowering Agents
may increase the hypotensive effect of Blood Pressure Lowering Agents
sodium thiosulfate & sodium nitriteÂ
may have an increasingly adverse effect when combined with sodium nitrite
may increase the hypotensive effect of Blood Pressure Lowering Agents
may increase the toxic effect of Local Anesthetics
may increase the adverse effects when combined
may have an increasingly adverse effect when combined with methemoglobinemia agents
may increase the adverse effect of local anesthetics
may increase the hypotensive effect of Blood Pressure Lowering Agents
may decrease the hypotensive effect of Blood Pressure Lowering Agents
may enhance the toxic effect of each other when combined
may enhance the toxic effect of each other when combined
may enhance the toxic effect of each other when combined
may enhance the toxic effect of each other when combined
may enhance the toxic effect of each other when combined
It may enhance the risk of adverse effects when combined with Barbiturates
It may enhance the risk of adverse effects when combined with Barbiturates
It may enhance the risk of adverse effects when combined with Barbiturates
It may enhance the risk of adverse effects when combined with Barbiturates
It may enhance the risk of adverse effects when combined with Barbiturates
It may enhance the risk of adverse effects when combined with Hypnotics
pneumococcal vaccine 13-valent
It may enhance the risk of adverse effects when combined with Hypnotics
pneumococcal vaccine heptavalent
It may enhance the risk of adverse effects when combined with Hypnotics
pneumococcal vaccine polyvalent
It may enhance the risk of adverse effects when combined with Hypnotics
may increase the hypotensive effect of barbiturates
dichlorphenamide : it may increase the toxic effect of Methemoglobinemia Associated Agents
cimetidine : it may increase the toxic effect of Methemoglobinemia Associated Agents
bupropion : it may increase the toxic effect of Methemoglobinemia Associated Agents
amphetamine : it may increase the toxic effect of Methemoglobinemia Associated Agents
guanethidine : it may increase the toxic effect of Methemoglobinemia Associated Agents
labetalol : it may increase the toxic effect of Methemoglobinemia Associated Agents
tramadol : it may increase the toxic effect of Methemoglobinemia Associated Agents
the rate of metabolism of norethynodrel may be increased
the therapeutic activity of butalbital may be reduced
an increase in CNS depression may be seen
azithromycin: it may increase the risk of methemoglobinemia agents
betaine: it may increase the risk of methemoglobinemia agents
bevacizumab: it may increase the risk of methemoglobinemia agents
abiraterone: it may increase the risk of methemoglobinemia agents
acetohexamide: it may increase the risk of methemoglobinemia agents
bedaquiline: it may increase the risk of methemoglobinemia agents
benazepril: it may increase the risk of methemoglobinemia agents
calfactant: it may increase the risk of methemoglobinemia agents
cannabidiol: it may increase the risk of methemoglobinemia agents
penfluridol: it may increase the risk of methemoglobinemia agents
pentoxyverine: it may increase the risk of methemoglobinemia agents
acenocoumarol: it may increase the risk of methemoglobinemia agents
the metabolism of acenocoumarol may be enhanced when combined with butalbital
the combination of butalbital and acetazolamide may increase the risk or extent of CNS depression
the concurrent use of butalbital with acetophenazine might amplify the risk or severity of CNS depression
the risk or extent of CNS depression can be heightened when butalbital is used in conjunction with zaleplon
the metabolism of zanubrutinib may see an increase when combined with butalbital
When butalbital is used together with lomitapide, this leads to an enhancement in lomitapide’s metabolism
bacitracin: it may decrease the excretion rate of metheglobinemia associated agents
baclofen: it may decrease the excretion rate of metheglobinemia associated agents
baricitinib: it may decrease the excretion rate of metheglobinemia associated agents
capreomycin: it may decrease the excretion rate of metheglobinemia associated agents
carbamazepine: it may decrease the excretion rate of metheglobinemia associated agents
carbidopa: it may decrease the excretion rate of metheglobinemia associated agents
diclofenac: it may decrease the excretion rate of metheglobinemia associated agents
diclofenamide: it may decrease the excretion rate of metheglobinemia associated agents
dicyclomine: it may decrease the excretion rate of metheglobinemia associated agents
diflunisal: it may decrease the excretion rate of metheglobinemia associated agents
diflucortolone: it may decrease the excretion rate of metheglobinemia associated agents
chloroprocaine: it may increase the risk of methemoglobinemia associated agents
cinoxacin: it may increase the risk of methemoglobinemia associated agents
ciprofloxacin: it may increase the risk of methemoglobinemia associated agents
doxacurim: it may increase the risk of methemoglobinemia associated agents
estradiol: it may increase the risk of methemoglobinemia associated agents
pyronaridine: it may increase the risk of methemoglobinemia associated agents
perphenazine: it may increase the risk of methemoglobinemia associated agents
celiprolol: it may increase the risk of methemoglobinemia associated agents
chlorothiazide: it may increase the risk of methemoglobinemia associated agents
chlorpromazine: it may increase the risk of methemoglobinemia associated agents
ergometrine: it may increase the risk of methemoglobinemia associated agents
cinnarizine and dimenhydrinateÂ
this combination will make you feel sleepy or tired when Tranquillisers used in combination
cinnarizine and dimenhydrinateÂ
this combination will make you feel sleepy or tired when Tranquillisers used in combination
When used with sedatives, eschscholzia californica can show addictive properties
CNS depressants increases the concentration of serum barbiturates in the serum
CNS depressants increases the concentration of serum barbiturates in the serum
CNS depressants increases the concentration of serum barbiturates in the serum
CNS depressants increases the concentration of serum barbiturates in the serum
CNS depressants increases the concentration of serum barbiturates in the serum
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
may decrease the level by affecting the hepatic enzyme CYP3A4 metabolism
Actions and Spectrum:Â
Actions:Â
Butalbital, categorized as a barbiturate, functions by replicating the inhibitory effects of gamma-aminobutyric acid (GABA). It attaches to a site distinct from the benzodiazepine binding site on the GABA receptor, leading to a prolongation of the GABA-mediated opening of chloride channels. This amplifies the inhibitory impact of GABA, resulting in physiological effects such as sedation, reduction of anxiety, hypnosis, and respiratory depression. The drug also induces tolerance and dependence.Â
Spectrum:Â
The combination of butalbital, caffeine, and aspirin is utilized to alleviate symptoms linked to tension (or muscle contraction) headaches. Continuous and repeated usage of this product is not recommended.Â
Butalbital is classified under the medication group known as barbiturates, exerting its effects within the central nervous system (CNS). Caffeine, functioning as a CNS stimulant, is employed alongside pain relievers to amplify their effectiveness. It has also been employed in managing migraine headaches. Â
Aspirin is employed for pain relief and reducing fever, falling into the category of medicines called salicylates. It acts on the immune system to reduce inflammation and is acknowledged as an anti-inflammatory analgesic. Codeine, categorized as a narcotic analgesic (pain medicine), acts on the central nervous system (CNS) to alleviate pain.Â
Extended or excessive use of butalbital may result in habituation, leading to mental or physical dependence. Sudden discontinuation of the medication may precipitate withdrawal side effects, and in individuals susceptible to headaches, the initial symptom of withdrawal may present as new (rebound) headaches.Â
Â
Frequency not definedÂ
Black Box Warning:Â
Butalbital is a potent central nervous system depressant with sedative properties, inducing sleepiness. This medication has the capability to modify brain function, reduce motor activity, diminish sensory perception, and result in hypnosis, sedation, and dose-dependent respiratory depression. It may also lead to the occurrence of nightmares and hallucinations.
Due to the presence of a robust barbiturate in its composition, Butalbital carries the potential for abuse and addiction. Prolonged use exceeding one month can alter brain chemistry, creating a dependency where the brain requires the drug to function properly. Abrupt cessation of the drug can trigger severe symptoms in the user.Â
Contraindication/Caution:Â
ContraindicationsÂ
CautionsÂ
Pregnancy consideration:Â Â
No data is available regarding the administration of the drug during pregnancy.Â
Breastfeeding warnings:Â Â
No data is available regarding the excretion of drug in breast milk.Â
Pregnancy category:Â
Category A: well-controlled and satisfactory studies show no risk to the fetus in the first or later trimester.Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: No data is available for the drug under this category.Â
Pharmacology:Â
Butalbital/caffeine/aspirin is a combination drug composed of butalbital, caffeine, and aspirin designed to alleviate tension headaches. Sudden discontinuation of the medication after prolonged use may lead to the development of habituation and result in discomforting symptoms.Â
Pharmacodynamics:Â
Butalbital, also recognized as 5-allyl-5-isobutylbarbituric acid, falls under the category of barbiturates and displays an intermediate duration of action. Various combinations containing butalbital have been approved, with Fioricet with Codeine (butalbital, caffeine, acetaminophen, and codeine phosphate) being one such combination.
This formulation is intended for alleviating the symptom complex associated with tension (or muscle contraction) headaches. However, there is a scarcity of available evidence supporting the safety and effectiveness of Fioricet with Codeine in treating multiple recurrent headaches.Â
Upon absorption from the gastrointestinal tract, butalbital is anticipated to distribute widely throughout the body’s tissues. It possesses the potential to appear in breast milk and readily traverse the placental barrier. Monoamine oxidase (MAO) inhibitors may augment the central nervous system (CNS) effects of butalbital.Â
The proposed mechanism of action for butalbital entails binding at a specific site linked to a chloride ionopore on the GABAA receptor. This binding extends the duration during which the chloride ionopore remains open, leading to a prolonged post-synaptic inhibitory effect of gamma-aminobutyric acid (GABA) in the thalamus.Â
Pharmacokinetics:Â
AbsorptionÂ
The time to achieve peak effect is 3-4 hoursÂ
Well absorbedÂ
DistributionÂ
Protein-bound is 45%Â
Elimination and ExcretionÂ
The half-life is 35 hoursÂ
The drug is excreted 59-88% in urine.Â
Administration:Â
The capsule and tablet containing a combination of butalbital, caffeine, and aspirin are meant to be taken orally. Typically, it is taken every 4 hours as required. It’s important to follow the instructions on your prescription label meticulously, and if there’s any part you find unclear, consult your doctor or pharmacist for clarification. Take butalbital, caffeine, and aspirin precisely as directed, and avoid exceeding six tablets or capsules in a single day.Â
Patient information leafletÂ
Generic Name: butalbitalÂ
Pronounced: byoo-TAL-bi-tawlÂ
Why do we use butalbital?Â
Butalbital is a medication primarily used for the treatment of tension headaches. It is often combined with other substances, such as caffeine and acetaminophen or aspirin, to enhance its effectiveness. Butalbital belongs to barbiturates, and it exerts its effects by acting on the central nervous system to produce sedation and reduce anxiety.Â
The combination of butalbital with other ingredients is believed to provide relief from tension headaches by addressing different aspects of the headache, such as muscle tension and pain. However, it’s important to note that the use of butalbital-containing medications should be carefully managed due to the potential for dependence and tolerance. Additionally, these medications are generally recommended for short-term use, and prolonged or excessive use may lead to adverse effects.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
